OBJECTIVE: This study aims to corroborate recent research demonstrating that patients with low body mass indexes tend to have worse postoperative survival outcomes compared to normal BMI patients. It also intends to compare survival outcomes and postoperative complications in transcatheter and surgical aortic valve replacement patients to determine which procedure, TAVR or SAVR respectively, is better for this challenging low BMI patient population. METHODS: This is a retrospective, single-center study comparing patient data collected from 2000-2013 at New York Presbyterian Hospital/Columbia University Medical Center. Patients were dividing into three groups on the basis of BMI and aortic valve procedure: low BMI SAVR (BMI < 22 kg/m2; n = 148; 20.36%), normal BMI SAVR (22-25 kg/m2; n = 458; 63.00%), and low BMI TAVR (< 22 kg/m2; n = 121; 16.64%). There is a total of 606 SAVR patients and 121 TAVR patients. To corroborate recent research that low BMI patients tend to fare worse than normal BMI patients, an unadjusted comparison were used to compare baseline demographics and postoperative outcomes of 148 low BMI patients who underwent SAVR with 458 normal BMI patients who underwent isolated SAVR. These cohorts were then compared via a Kaplan-Meier survival analysis and the log-rank test for 30 days, 6 months, 1 year and 3 years survival outcomes. The 148 low BMI SAVR patients were then compared to 121 low BMI patients who underwent TAVR on baseline demographics and preoperative risk factors. The two cohorts were compared using the Kaplan-Meier analysis and postoperative complications were compared utilizing a multivariable logistic regression after adjustment for age, gender, BMI and STS Scores. RESULTS: The unadjusted analysis of the low BMI and normal BMI SAVR cohorts displayed similar patient demographics and preoperative risk factors. The normal BMI group demonstrated higher EF (55% vs. 51.5%; p = 0.002) and incidence of HLD (47.68% vs. 37.76%; p = 0.038). Conversely, the low BMI cohort had more females (61.49% vs.42.79%; p < 0.001) and individuals with a history of Afib (27.78% vs.16.96%; p = 0.004). As shown in the Kaplan Meier curve, the normal BMI SAVR patients exhibited superior 6 months, 1 year and 3 years survival rates and low BMI was shown to be a significant independent predictor of mortality (HR 2.56; 95% CI: 1.47 – 4.47; p = 0.0009 at 1 year). The two groups had similar postoperative outcomes, however, the low BMI cohort had longer overall hospital stays (8 vs. 6.5 days; p = 0.0003). The low BMI SAVR and TAVR patient cohorts varied significantly on most patient demographics and preoperative risk factors. The low BMI TAVR patients tend to be older (95.04% vs. 55.41% of patients > 75 years old) and had higher STS Scores (10.41 vs. 3.88; p < 0.0001). They also demonstrated significant increases in all the preoperative risk factors excluding DM and prior CVA. The SAVR patients had significantly longer overall hospital stays (8 vs. 6 days; p < 0.0001), more re-exploration for bleeding (5.41% vs. 0.85%; p = 0.0411) and more patients discharged to home (68.24% vs. 50.85%; p = 0.0039) while the TAVR patients demonstrated higher rates of GI bleed (3.39% vs. 0.00%; p = 0.0240) and new PPM (10.17% vs. 0.68%; p = 0.0004). The low BMI SAVR cohort demonstrated better survival rates at 1 year and 3 years and low BMI TAVR was determined to be a significant independent predictor of mortality (HR 0.51; 95% CI: 0.30 – 0.88; p = 0.0146 at 1 year). After controlling for specific covariates in the multivariate logistic regression analysis, the low BMI SAVR had 1.73 times longer ICU stays, 1.90 times longer hospital stays and the odds of being discharged home was 17% less than the TAVR group (p = 0.0005, <0.0001, 0.5665). CONCLUSION: Although the rates of postoperative complications are fairly similar, patients with low BMIs demonstrated worse survival outcomes when compared to the normal BMI SAVR patients. With the current analysis, low BMI TAVR patients had a significantly worse preoperative profile compared to the corresponding SAVR cohort which explains the worse survival and postoperative outcomes. Despite this, the multivariable analysis showed that the low BMI SAVR patients had longer ICU and hospital stays as well as fewer discharges to home. As this is an ongoing study, steps should be made to balance the preoperative profile such that the low BMI SAVR and TAVR groups are comparable prior to survival and postoperative assessment. However, at the current status, TAVR has proven itself to be the preferred treatment for low BMI patients. / 2018-07-13T00:00:00Z

No description available.

Background “valve-in-valve” TAVR (VIV-TAVR) is established and provides good initial clinical and hemodynamic outcomes. Lacking long-term durability data baffle the expand to lower risk patients. For those purposes, the present study adds a hemodynamic 3-years follow-up. Methods A total of 77 patients underwent VIV-TAVR for failing aortic bioprosthesis during a 7-years period. Predominant mode of failure was stenosis in 87.0%. Patients had a mean age of 79.4 ± 5.8 years and a logistic EuroSCORE of 30.8 ± 15.7%. The Society of Thoracic Surgeons-PROM averaged 5.79 ± 2.63%. Clinical results and hemodynamic outcomes are reported for 30-days, 1-, 2-, and 3-years. Completeness of follow-up was 100% with 44 patients at risk after 3-years. Follow-up ranged up to 7.1 years. Results Majority of the surgical valves were stented (94.8%) with a mean labeled size of 23.1 ± 2.3 mm and true-ID of 20.4 ± 2.6 mm. A true-ID ≤21 mm had 58.4% of the patients. Self-expanding valves were implanted in 68.8% (mean labeled size 24.1 ± 1.8 mm) and balloon-expanded in 31.2% (mean size 24.1 ± 1.8 mm). No patient died intraoperatively. Hospital mortality was 1.3% and three-years survival 57.1%. All patients experienced an initial significant dPmean-reduction to 16.8 ± 7.1 mmHg. After 3-years mean dPmean raised to 26.0 ± 12.2 mmHg. This observation was independent from true-ID or type of transcatheter aortic valve replacement (TAVR)-prosthesis. Patients with a true-ID ≤21 mm had a higher initial (18.3 ± 5.3 vs. 14.9 ± 7.1 mmHg; p = .005) and dPmean after 1-year (29.2 ± 8.2 vs. 13.0 ± 6.7 mmHg; p = .004). There were no significant differences in survival. Conclusions VIV-TAVR is safe and effective in the early period. In surgical valves with a true-ID ≤21 mm inferior hemodynamic and survival outcomes must be expected. Nonetheless, also patients with larger true-IDs showed steadily increasing transvalvular gradients. This raises concern about durability.

No description available.

Ischemia caused by particles becoming dislodged during transcatheter aortic valve replacement (TAVR) is a possible complication of TAVR. The particles that become dislodged can travel out of the aortic valve, into the aortic arch, and then into either the brachiocephalic artery, the left common carotid artery, the left subclavian artery or continue into the descending aorta. If the particles continue into the descending aorta it poses no risk of causing ischemia however if it travels into the other arteries then it increases the possibility of the particle causing an ischemic event. The goal of this study is to determine what parameters cause the particle to enter one artery over another. The parameters analyzed are the particle diameter, the particle density, the blood pressure, and the diameter of the catheter used in the surgery. This was done by creating a finite element model in COMSOL Multiphysics® to track the particles flowing through a scan of an actual aortic arch. It was determined that the particle diameter, particle density, and the blood pressure affect which artery the particles take to exit the aortic arch. However the diameter of the surgical catheter used in a transaortic approach is not statistically significant when determining which artery the particles will exit. The study shows that larger diameter particle would lead to a higher transmissions probability into the brachiocephalic artery, the left common carotid artery, and the left subclavian artery while a smaller diameter particle would have a higher transmission probability for the descending aorta. Averaging all particle diameters, densities and blood pressure found that 54.95 ± 13.66% of the particles released will travel into the cerebral circulatory system.

L’incidence et la prévalence des maladies valvulaires sont en augmentation, l’épidémiologie de ces maladies se modifie avec une prépondérance des maladies dégénératives, et le traitement considéré est le plus souvent le remplacement valvulaire prothétique, notamment dans le cadre de la sténose aortique qui est la maladie valvulaire la plus fréquente. Les techniques de remplacement valvulaire et les prothèses valvulaires ont grandement évolué ces dernières années, notamment avec le développement des implantations de prothèses par voie percutanée. Cependant les substituts valvulaires aortiques biologiques sont exposés à des complications diverses mettant en jeu la fonction de la prothèse : fuite péri-prothétique, endocardite infectieuse, dégénérescence des tissus biologiques. Ces complications restent des challenges diagnostiques et l’échographie est l’imagerie de référence. Cependant, l’imagerie cardiaque et valvulaire a réalisé de grands progrès, et l’utilisation d’autres techniques ou modalités d’imagerie peut être une alternative ou un complément à l’exploration par échocardiographie : imagerie par scanner, imagerie par résonance magnétique, imagerie nucléaire. Le recours et la combinaison de ces différentes techniques s’intègrent dans une approche globale, nommée imagerie multimodale. L’objectif général de ce projet de doctorat a été d’étudier l’apport de l’imagerie multimodale dans la surveillance des bioprothèses aortiques et l’évaluation des complications et de la dégénérescence structurelle qui peuvent survenir. / The incidence and prevalence of heart valve diseases are increasing worldwide. Their epidemiology also changes, and the required treatment is most often a prosthetic valve replacement, especially for aortic stenosis that is the most frequent heart valve disease. Techniques of valve replacement as well as prosthesis themselves have dramatically evolved in recent years, especially with the development of percutaneous transcatheter procedures. However, biologic aortic valve substitutes are at risk of several complications including prosthetic valve dysfunction, paravalvular regurgitation, infective endocarditis and structural valve deterioration. Correctly diagnose any of these complications still is a challenge but echocardiography plays a pivotal role and remains the gold-standard as per diagnostic imaging. Nonwithsanding the fact that echocardiography is the main imaging modality for valvular anomalies, great progress has been made in cardiac imaging and modalities like CT-Scan, MRI and nuclear imaging are nowadays regularly used along with echocardiography. The use and combination of these different techniques are part of a global approach, entitled multi-modality imaging.The general objective of this doctoral project was to study the contribution of the multi-imaging approach in the assessment of the bioprosthesis function and screening for complications and structural valve deterioration that may occur.

No description available.

Leaflet replacement in aortic valve repair (AVr) is associated with increased long-term repair failure. Hemodynamic performance and mechanical stress levels were investigated after porcine AVr with 5 types of clinically relevant replacement materials to ascertain which material(s) would be best suited for repair. Porcine aortic roots with intact aortic valves were placed in a left-heart simulator mounted with a high-speed camera for baseline valve assessment. Then, the non-coronary leaflet was excised and replaced with autologous porcine pericardium (APP), glutaraldehyde-fixed bovine pericardial patch (BPP; Synovis™), extracellular matrix scaffold (CorMatrix™), or collagen-impregnated Dacron (HEMASHIELD™). Hemodynamic parameters were measured over a range of cardiac outputs (2.5–6.5L/min) post-repair. Material properties of the above materials along with St. Jude Medical™ Pericardial Patch with EnCapTM Technology (SJM) were determined using pressurization experiments. Finite element models of the aortic valve and root complex were then constructed to verify the hemodynamic characteristics and determine leaflet stress levels. This study demonstrates that APP and SJM have the closest profiles to normal aortic valves; therefore, use of either replacement material may be best suited. Increased stresses found in BPP, HEMASHIELD™, and CorMatrix™ groups may be associated with late repair failure.

Leaflet replacement in aortic valve repair (AVr) is associated with increased long-term repair failure. Hemodynamic performance and mechanical stress levels were investigated after porcine AVr with 5 types of clinically relevant replacement materials to ascertain which material(s) would be best suited for repair. Porcine aortic roots with intact aortic valves were placed in a left-heart simulator mounted with a high-speed camera for baseline valve assessment. Then, the non-coronary leaflet was excised and replaced with autologous porcine pericardium (APP), glutaraldehyde-fixed bovine pericardial patch (BPP; Synovis™), extracellular matrix scaffold (CorMatrix™), or collagen-impregnated Dacron (HEMASHIELD™). Hemodynamic parameters were measured over a range of cardiac outputs (2.5–6.5L/min) post-repair. Material properties of the above materials along with St. Jude Medical™ Pericardial Patch with EnCapTM Technology (SJM) were determined using pressurization experiments. Finite element models of the aortic valve and root complex were then constructed to verify the hemodynamic characteristics and determine leaflet stress levels. This study demonstrates that APP and SJM have the closest profiles to normal aortic valves; therefore, use of either replacement material may be best suited. Increased stresses found in BPP, HEMASHIELD™, and CorMatrix™ groups may be associated with late repair failure.